Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
1. A recombinant nonpathogenic Marek's Disease Virus (rMDV np ) comprising a first nucleic acid inserted in a first nonessential site in the rMDV np genome and a second nucleic acid inserted in a second nonessential site in the rMDV np genome;
wherein the first nucleic acid comprises both a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein D (ILTVgD) and a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein I (ILTVgl);
wherein the second nucleic acid comprises a nucleotide sequence that encodes a Newcastle Disease Virus fusion protein (NDV F);
wherein the first nonessential site and the second nonessential site are either both the UL54.5 site or only the first nonessential site is the US2 site; and
wherein the rMDV np is not a recombinant avian herpesvirus comprising a Marek's disease virus (MDV) unique short viral genome region, a herpesvirus of turkeys (HVT) unique long viral genome region, and the repeat viral genome regions of the HVT.
2. The rMDV np of claim 1 , wherein the first nonessential site is the US2 site and the second nonessential site is the UL7/8 site.
3. The rMDV np of claim 1 , wherein the nucleotide sequence encoding the ILTV gD protein is operatively under the control of a first promoter, the nucleotide sequence encoding the ILTV gl protein is operatively under the control of a second promoter, and the nucleotide sequence encoding the NDV F protein is operatively under the control of a third promoter.
4. The rMDV np of claim 3 , wherein the first promoter, the second promoter, and the third promoter are all different.
5. The rMDV np of claim 4 , wherein the first promoter is the endogenous ILTV gD promoter and the second promoter is the endogenous ILTV gl promoter.
6. The rMDV np of claim 5 , wherein the third promoter is the human cytomegalovirus immediate early (hCMV IE) promoter.
7. The rMDV np of claim 6 that is a recombinant herpesvirus of turkeys (rHVT).
8. A vaccine comprising the rMDV np of claim 1 .
9. The vaccine of claim 8 , wherein the rMDV np is a recombinant herpesvirus of turkeys (rHVT).
10. The vaccine of claim 9 , that further comprises a mild live infectious bursal disease virus (IBDV).
11. The vaccine of claim 10 , wherein the mild live IBDV is strain 89/03.
12. A vaccine comprising the rMDV np of claim 2 .
13. The vaccine of claim 12 , that further comprises a mild live IBDV.
14. The vaccine of claim 13 , wherein the mild live IBDV is strain 89/03.
15. A method for aiding in the protection of a chicken against ILTV comprising administering the vaccine of claim 14 .
16. A method for aiding in the protection of a chicken against ILTV comprising administering the vaccine of claim 8 .
17. The vaccine of claim 12 , wherein the rMDV np is a recombinant herpesvirus of turkeys (rHVT).
18. The vaccine of claim 17 , that further comprises an attenuated infectious bursal disease virus (IBDV).
19. A vaccine comprising the rMDV np of claim 5 .
20. The vaccine of claim 19 , wherein the rMDV np is a recombinant herpesvirus of turkeys (rHVT).
21. The vaccine of claim 20 , that further comprises an attenuated infectious bursal disease virus (IBDV).